The discovery of new diseases often follows a pattern. Scattered patients realise they are experiencing strange symptoms. They find each other, face to face in a neighbourhood or across the world on the internet. They bring their experience to medicine, and medicine is sceptical. And then, after a period of pain and recalcitrance, medicine admits that, in fact, the patients were right.
That is the story of the discovery of CFS/ME and Lyme disease, among others. But it is not the story of alpha-gal allergy. An odd set of coincidences brought this bizarre illness to the attention of researchers almost as soon as it occurred.
The story begins with a cancer drug called cetuximab, which came on to the market in 2004. Cetuximab is a protein grown in cells taken from mice. For any new drug, there are likely to be a few people that react badly to it, and that was true for cetuximab. In its earliest trials, one or two of every 100 cancer patients who had it infused into their veins had a hypersensitive reaction: their blood pressure dropped and they had difficulty breathing.